Advances in the research on lymphangiogenesis in carcinoma tissues (Review)

Qiu,Xiaofei; Yao,Shujuan; Zhang,Shiqian

doi:10.3892/ol_00000102

Advances in the research on lymphangiogenesis in carcinoma tissues (Review)

Authors:
- Xiaofei Qiu
- Shujuan Yao
- Shiqian Zhang
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The Centre People's Hospital of Tengzhou, Tengzhou 277500, P.R. China
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000102
Pages: 579-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic spread of tumors is an important prognostic factor for cancer patients. The effect of angiogenesis on cancer cell proliferation and metastatic spread has been confirmed. However, less attention has been focused on research involving tumor lymphangiogenesis as opposed to research on tumor angiogenesis, due to the lack of specific markers for lymphatic vessel endothelial cells (LVECs). Recently, the improvement of isolation techniques for LVECs and the discovery of specific LVEC markers such as vascular endothelial growth factor receptor-3 (VEGFR-3), podoplanin, lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and Prox1 have led to advances in research involving lymphangiogenesis in carcinoma tissues. New lymphatic vessels in tumor tissues may originate from bone marrow endothelial progenitor cells, directly from the preexisting lymphatic vessels, and even by cell transformation. Peritumoral lymphatic vessels play a more important role in the process of tumor metastasis by providing more channels for lymphatic invasion and metastatic spread. The molecular mechanism of tumor lymphangiogenesis is complicated, and numerous factors such as VEGF-A, platelet-derived growth factors (PDGFs), hepatocyte growth factor (HGF), fibroblast growth factor-2 (FGF-2), and angiopoietins (Ang) are directly or indirectly involved in the process. However, it has been demonstrated that the VEGF-C/VEGF-D/VEGFR-3 signaling pathways are the most important mechanism underlying tumor lymphangiogenesis.

View Figures

View References

1	Schacht V, Ramirez MI, Hong YK, et al: T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22:3546–3556. 2003. View Article : Google Scholar : PubMed/NCBI
2	Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
3	Wigle JT, Harvey N, Detmar M, et al: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21:1505–1513. 2002. View Article : Google Scholar : PubMed/NCBI
4	Salven P, Mustjoki S, Alitalo R, Alitalo K and Rafii S: VEGFR-3 and CD133 identify a population of CD34⁺ lymphatic/vascular endothelial precursor cells. Blood. 101:168–172. 2003. View Article : Google Scholar : PubMed/NCBI
5	He Y, Rajantie I, Ilmonen M, et al: Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 64:3737–3740. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kerjaschki D: The crucial role of macrophages in lymphangiogenesis. J Clin Invest. 115:2316–2319. 2005. View Article : Google Scholar : PubMed/NCBI
7	Ji RC and Kato S: Lymphatic network and lymphangiogenesis in the gastric wall. J Histochem Cytochem. 51:331–338. 2003. View Article : Google Scholar : PubMed/NCBI
8	Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K and Harkonen PL: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer. 98:946–951. 2002. View Article : Google Scholar : PubMed/NCBI
9	Franchi A, Massi D, Santucci M, et al: Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol. 208:439–445. 2006. View Article : Google Scholar : PubMed/NCBI
10	Koike C, McKee TD, Pluen A, et al: Solid stress facilitates spheroid formation: potential involvement of hyaluronan. Br J Cancer. 86:947–953. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kato S, Shimoda H, Ji RC and Miura M: Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers. Anat Sci Int. 81:71–83. 2006. View Article : Google Scholar : PubMed/NCBI
12	Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S and Ristamaki R: Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 63:1920–1926. 2003.
13	Sipos B, Klapper W, Kruse ML, Kalthoff H, Kerjaschki D and Kloppel G: Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol. 165:1187–1197. 2004. View Article : Google Scholar : PubMed/NCBI
14	Padera TP, Kadambi A, di Tomaso E, et al: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 296:1883–1886. 2002. View Article : Google Scholar : PubMed/NCBI
15	Straume O, Jackson DG and Akslen LA: Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 9:250–256. 2003.PubMed/NCBI
16	Saintigny P, Kambouchner M, Ly M, et al: Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 58:205–213. 2007. View Article : Google Scholar : PubMed/NCBI
17	Brakenhielm E, Burton JB, Johnson M, et al: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer. 121:2153–2161. 2007. View Article : Google Scholar : PubMed/NCBI
18	Karkkainen MJ, Haiko P, Sainio K, et al: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 5:74–80. 2004. View Article : Google Scholar : PubMed/NCBI
19	Haiko P, Makinen T, Keskitalo S, et al: Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol. 28:4843–4850. 2008. View Article : Google Scholar : PubMed/NCBI
20	Stacker SA, Caesar C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 7:186–191. 2001. View Article : Google Scholar : PubMed/NCBI
21	Lin J, Lalani AS, Harding TC, et al: Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65:6901–6909. 2005. View Article : Google Scholar : PubMed/NCBI
22	Makinen T, Jussila L, Veikkola T, et al: Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 7:199–205. 2001. View Article : Google Scholar : PubMed/NCBI
23	Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA and Silverman JF: Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol. 19:1317–1323. 2006. View Article : Google Scholar : PubMed/NCBI
24	Whitehurst B, Flister MJ, Bagaitkar J, et al: Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer. 121:2181–2191. 2007. View Article : Google Scholar : PubMed/NCBI
25	Cao R, Bjorndahl MA, Religa P, et al: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 6:333–345. 2004. View Article : Google Scholar : PubMed/NCBI
26	Cao R, Bjorndahl MA, Gallego MI, et al: Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood. 107:3531–3536. 2006. View Article : Google Scholar : PubMed/NCBI
27	Björndahl M, Cao R, Nissen LJ, et al: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 102:15593–15598. 2005.PubMed/NCBI
28	Chang LK, Garcia-Cardena G, Farnebo F, et al: Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA. 101:11658–11663. 2004. View Article : Google Scholar : PubMed/NCBI
29	Morisada T, Oike Y, Yamada Y, et al: Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 105:4649–4656. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Wu K, Zhang D, et al: Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun. 337:386–393. 2005. View Article : Google Scholar : PubMed/NCBI